CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs
- PMID: 24850760
- DOI: 10.1182/blood-2013-12-546416
CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs
Abstract
Myeloid-derived suppressor cells (MDSCs) represent a heterogeneous population that shares certain characteristics including an aberrant myeloid phenotype and the ability to suppress T cells. MDSCs have been predominantly studied in malignant diseases and findings suggest involvement in tumor-associated immune suppression. Chronic lymphocytic leukemia (CLL) is the leukemia with the highest incidence among adults. Immune defects occur already at early disease stages and impact the clinical course. We assessed presence, frequency, association to other immune parameters, and functional properties of circulating CD14(+) cells lacking HLA-DR expression (HLA-DR(lo)) in patients with untreated CLL. These monocytic cells represent one of the best-defined human MDSC subsets. Frequency of CD14(+)HLA-DR(lo) cells was significantly increased in CLL patients. Furthermore, MDSCs suppressed in vitro T-cell activation and induced suppressive regulatory T cells (TRegs). The MDSC-mediated modulation of T cells could be attributed to their increased indoleamine 2,3-dioxygenase (IDO) activity. CLL cells induced IDO(hi) MDSCs from healthy donor monocytes suggesting bidirectional crosstalk between CLL-cells, MDSCs, and TRegs. Overall, we identified a MDSC population that expands in CLL. The exact mechanisms responsible for such accumulation remain to be elucidated and it will be of interest to test whether antagonizing suppressive functions of CLL MDSCs could represent a mean for enhancing immune responses.
© 2014 by The American Society of Hematology.
Comment in
-
MDSCs: the final frontier of the microenvironment in CLL?Blood. 2014 Jul 31;124(5):666-8. doi: 10.1182/blood-2014-06-578880. Blood. 2014. PMID: 25082859 Free PMC article.
Similar articles
-
Immunosuppressive CD14+HLA-DRlow/neg IDO+ myeloid cells in patients following allogeneic hematopoietic stem cell transplantation.Leukemia. 2013 Feb;27(2):377-88. doi: 10.1038/leu.2012.215. Epub 2012 Jul 25. Leukemia. 2013. PMID: 22828446
-
Tumor-induced CD14+HLA-DR (-/low) myeloid-derived suppressor cells correlate with tumor progression and outcome of therapy in multiple myeloma patients.Cancer Immunol Immunother. 2015 Mar;64(3):389-99. doi: 10.1007/s00262-014-1646-4. Epub 2014 Dec 30. Cancer Immunol Immunother. 2015. PMID: 25548095 Free PMC article.
-
Vasoactive intestinal peptide induces CD14+HLA-DR‑/low myeloid-derived suppressor cells in gastric cancer.Mol Med Rep. 2015 Jul;12(1):760-8. doi: 10.3892/mmr.2015.3374. Epub 2015 Feb 18. Mol Med Rep. 2015. PMID: 25695487
-
The CD14+HLA-DRlo/neg Monocyte: An Immunosuppressive Phenotype That Restrains Responses to Cancer Immunotherapy.Front Immunol. 2019 May 22;10:1147. doi: 10.3389/fimmu.2019.01147. eCollection 2019. Front Immunol. 2019. PMID: 31191529 Free PMC article. Review.
-
Beyond bystanders: Myeloid cells in chronic lymphocytic leukemia.Mol Immunol. 2019 Jun;110:77-87. doi: 10.1016/j.molimm.2017.11.014. Epub 2017 Nov 22. Mol Immunol. 2019. PMID: 29173971 Review.
Cited by
-
Targeting T regulatory (Treg) cells in immunotherapy-resistant cancers.Cancer Drug Resist. 2024 Jan 12;7:2. doi: 10.20517/cdr.2023.46. eCollection 2024. Cancer Drug Resist. 2024. PMID: 38318526 Free PMC article. Review.
-
cROSsing the Line: Between Beneficial and Harmful Effects of Reactive Oxygen Species in B-Cell Malignancies.Front Immunol. 2020 Jul 21;11:1538. doi: 10.3389/fimmu.2020.01538. eCollection 2020. Front Immunol. 2020. PMID: 32793211 Free PMC article. Review.
-
PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia.Blood. 2015 Jul 9;126(2):203-11. doi: 10.1182/blood-2015-01-622936. Epub 2015 Mar 23. Blood. 2015. PMID: 25800048 Free PMC article.
-
Anti-PD-L1/PD-L2 therapeutic vaccination in untreated chronic lymphocytic leukemia patients with unmutated IgHV.Front Oncol. 2022 Nov 22;12:1023015. doi: 10.3389/fonc.2022.1023015. eCollection 2022. Front Oncol. 2022. PMID: 36483037 Free PMC article.
-
Thrombospondin 1 Modulates Monocyte Properties to Suppress Intestinal Mucosal Inflammation.J Innate Immun. 2015;7(6):601-11. doi: 10.1159/000398799. Epub 2015 May 20. J Innate Immun. 2015. PMID: 25998580 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous